Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer.

Journal Article (Clinical Trial;Journal Article)

BACKGROUND: Both irinotecan and oxaliplatin are active agents in the treatment of patients with metastatic colorectal cancer (MCC). There is a strong preclinical rationale for combining these two agents. We sought to determine the dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) of combined irinotecan and oxaliplatin given every three weeks. METHODS: Cohorts of patients with MCC previously treated with 5-fluorouracil received escalating doses of irinotecan (150, 175, and 200 mg/m(2)) and a fixed dose of oxaliplatin (130 mg/m(2)), both given intravenously every 3 weeks. DLT was evaluated within the first course of treatment. Objective responses were evaluated every two courses and were confirmed at least four weeks later. RESULTS: Fourteen patients were treated and evaluated for toxicity. The DLT was neutropenia, with or without fever, and delayed recovery of neutrophil counts was frequent (13 courses in six patients). Other toxic effects (peripheral neuropathy, nausea, vomiting, diarrhea, and fatigue) were mild to moderate. Among 13 patients evaluable for activity, four achieved partial responses and nine had stable disease. CONCLUSION: The combination of irinotecan and oxaliplatin is safe and apparently active in the treatment of MCC patients. The recommended dose for phase II studies is 175 mg/m(2) irinotecan plus 130 mg/m(2) oxaliplatin, given every 3 weeks. Neutropenia and delayed recovery of neutrophil counts are the predominant early toxicities with this schedule.

Full Text

Duke Authors

Cited Authors

  • Hoff, PM; Saad, ED; Pazdur, R; Wolff, R; Lassere, Y; Bogaard, KR; Abbruzzese, JL

Published Date

  • August 2004

Published In

Volume / Issue

  • 22 / 3

Start / End Page

  • 307 - 313

PubMed ID

  • 15122078

International Standard Serial Number (ISSN)

  • 0167-6997

Digital Object Identifier (DOI)

  • 10.1023/B:DRUG.0000026257.31142.41


  • eng

Conference Location

  • United States